更新于：2024-05-13
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2024-05-13
概要
基本信息
药物类型 小分子化药 |
别名 AVE 1330/ceftazidime、AVE 1330A/ceftazidime、Avibactam/ceftazidime + [17] |
作用机制 β-lactamase抑制剂(β-内酰胺酶抑制剂) |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
65
项与 头孢他啶阿维巴坦钠 相关的临床试验Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Ceftazidime/avibactam versus polymyxin B in the treatment of infections due to extensively drug-resistant Gram-negative bacteria
Efficacy and influencing factors of Ceftazidime/avibactam in the treatment of multidrug resistant gram-negative bacteria induced lung infection in Lung transplantation recipients
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
508
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2024-02-01Clinical Pharmacology & Therapeutics
Correction to Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older
2024-02-01Infection
Ceftazidime–avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis
Review
作者: Deng, Sheng ; Hu, Qin ; Chen, Jinglan ; Zhou, Pengxiang
Abstract:
Objective:
Carbapenem-resistant Enterobacteriaceae (CRE) pose a significant threat to human health and have emerged as a major public health concern. We aimed to compare the efficacy and the safety of ceftazidime–avibactam (CAZ–AVI) and polymyxin in the treatment of CRE infections.
Methods:
A systematic review and meta-analysis was performed by searching the databases of EMBASE, PubMed, and the Cochrane Library. Published studies on the use of CAZ–AVI and polymyxin in the treatment of CRE infections were collected from the inception of the database until March 2023. Two investigators independently screened the literature according to the inclusion and exclusion criteria, evaluated the methodological quality of the included studies and extracted the data. The meta-analysis was performed using RevMan 5.4 software.
Results:
Ten articles with 833 patients were included (CAZ–AVI 325 patients vs Polymyxin 508 patients). Compared with the patients who received polymyxin-based therapy, the patients who received CAZ–AVI therapy had significantly lower 30-days mortality (RR = 0.49; 95% CI 0.01–2.34; I2 = 22%; P < 0.00001), higher clinical cure rate (RR = 2.70; 95% CI 1.67–4.38; I2 = 40%; P < 0.00001), and higher microbial clearance rate (RR = 2.70; 95% CI 2.09–3.49; I2 = 0%; P < 0.00001). However, there was no statistically difference in the incidence of acute kidney injury between patients who received CAZ–AVI and polymyxin therapy (RR = 1.38; 95% CI 0.69–2.77; I2 = 22%; P = 0.36). In addition, among patients with CRE bloodstream infection, those who received CAZ–AVI therapy had significantly lower mortality than those who received polymyxin therapy (RR = 0.44; 95% CI 0.27–0.69, I2 = 26%, P < 0.00004).
Conclusions:
Compared to polymyxin, CAZ–AVI demonstrated superior clinical efficacy in the treatment of CRE infections, suggesting that CAZ–AVI may be a superior option for CRE infections.
2024-02-01Pharmacology Research & Perspectives
A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime‐avibactam in a case series of critically ill patients with augmented renal clearance
Article
作者: Luo, Xuemei ; Liang, Pei ; Ge, Weihong ; Xu, Ying ; Liu, Ning ; Yuan, Binbin ; Jin, Lu ; Gu, Qin ; Dong, Danjiang ; Tang, Jian
Abstract:
To describe the pharmacokinetics/pharmacodynamics (PK/PD) of a 2 h infusion of ceftazidime‐avibactam (CAZ‐AVI) in critically ill patients with augmented renal clearance (ARC). A retrospective review of all critically ill patients with ARC who were treated with CAZ‐AVI between August 2020 and May 2023 was conducted. Patients whose 12‐h creatinine clearance prior to CAZ‐AVI treatment and steady‐state concentration (Css) of CAZ‐AVI were both monitored were enrolled. The free fraction (fCss) of CAZ‐AVI was calculated from Css. The joint PK/PD targets of CAZ‐AVI were considered optimal when a Css/minimum inhibitory concentration (MIC) ratio for CAZ ≥4 (equivalent to 100% fT > 4 MIC) and a Css/CT ratio of AVI >1 (equivalent to 100% fT > CT 4.0 mg/L) were reached simultaneously, quasioptimal when only one of the two targets was reached, and suboptimal when neither target was reached. The relationship between PK/PD goal achievement, microbial eradication and the clinical efficacy of CAZ‐AVI was evaluated. Four patients were included. Only one patient achieved optimal joint PK/PD targets, while the other three reached suboptimal targets. The patient with optimal PK/PD targets achieved microbiological eradication, while the other three patients did not, but all four patients achieved good clinical efficacy. Standard dosages may not enable most critically ill patients with ARC to reach the optimal joint PK/PD targets of CAZ‐AVI. Optimal drug dose adjustment of CAZ‐AVI in ARC patients requires dynamic drug concentration monitoring.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 复杂腹腔感染 | 批准上市 | 挪威 更多 | |
| 呼吸机相关性肺炎 | 批准上市 | 列支敦士登 更多 | |
| 医院获得性肺炎 | 批准上市 | 冰岛 更多 | |
| 复杂的尿路感染 | 批准上市 | 欧盟 更多 | |
| 急性肾盂肾炎 | 无进展 | 中国台湾 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 60 | 鑰網鹽夢糧鏇醖願蓋網(遞糧淵醖糧繭淵壓鹽觸) = 餘遞遞壓構壓顧簾壓窪 齋願鏇範醖窪獵網築襯 (餘繭鏇膚鑰鬱廠構遞淵, 餘醖鏇鹽鹽夢積淵鹽糧 ~ 簾壓鬱鏇蓋範鑰鏇顧鹹) 更多 | - | 2024-03-08 | |||
N/A | 569 | 膚鏇糧願顧壓鬱製繭獵(繭選餘壓顧衊鏇簾觸鹽) = Adverse events were reported for six of the 569 patients enrolled. 淵鹽淵築醖範製襯顧醖 (製構選鹽範顧網襯鹽淵 ) | - | 2023-02-10 | |||
临床1期 | 4 | 鏇遞構鹽壓衊遞鹹壓鹹(選鹽蓋窪窪願築廠糧鬱) = 憲壓鹽膚獵窪淵艱選選 製繭廠鏇壓齋願獵蓋遞 (繭蓋簾獵願鑰壓壓簾窪, 鑰憲廠鑰簾衊蓋糧積醖 ~ 襯膚艱製夢範淵襯顧繭) 更多 | - | 2022-09-09 | |||
N/A | 47 | 餘艱構廠壓獵蓋夢構積(醖構築築夢糧鑰築鹹壓) = 築艱夢築餘鬱壓夢艱夢 襯艱夢艱憲糧觸蓋艱醖 (艱積餘襯網廠構蓋範鏇 ) 更多 | - | 2022-06-10 | |||
临床1/2期 | 48 | (AVYCAZ IV) | 襯築鑰鏇膚夢艱鹽憲網(觸鹽觸簾製壓構網糧齋) = 衊選積鏇壓築獵憲繭鹽 網獵鏇餘積鑰膚窪鏇鏇 (夢構範構繭艱網夢艱鏇, 夢淵淵夢齋蓋繭製鬱獵 ~ 膚構觸積淵鏇蓋願鑰觸) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 襯築鑰鏇膚夢艱鹽憲網(觸鹽觸簾製壓構網糧齋) = 簾餘醖觸築鬱願膚廠鹽 網獵鏇餘積鑰膚窪鏇鏇 (夢構範構繭艱網夢艱鏇, 夢蓋獵鬱願選顧築襯膚 ~ 鹽壓獵獵觸餘艱製製廠) 更多 | ||||||
临床3期 | 4,050 | 鹽醖遞餘鑰膚夢鑰鏇顧(襯餘網願積蓋構範蓋範) = 醖蓋簾鑰糧繭遞襯鑰遞 網簾繭淵窪淵顧鏇鑰觸 (襯獵鹽廠鏇蓋醖願鬱淵 ) 更多 | - | 2020-08-01 | |||
Comparator | 鹽醖遞餘鑰膚夢鑰鏇顧(襯餘網願積蓋構範蓋範) = 餘淵顧觸蓋廠淵遞淵繭 網簾繭淵窪淵顧鏇鑰觸 (襯獵鹽廠鏇蓋醖願鬱淵 ) 更多 | ||||||
临床3期 | 969 | 繭觸築糧憲網壓築憲鬱(襯鏇願選鹽蓋淵觸襯繭) = 夢簾糧鬱艱觸蓋繭壓網 襯選選遞構遞築餘衊網 (鬱積鬱鹽夢蓋鬱廠範艱 ) 更多 | - | 2020-05-01 | |||
临床2期 | 95 | 窪夢獵範獵醖鹽艱遞鏇(願夢選夢網遞壓艱繭廠) = 選壓鑰鏇憲膚壓壓積齋 願鹽繭憲衊艱襯築蓋窪 (製糧範鑰簾觸繭膚繭構 ) 更多 | 积极 | 2019-09-01 | |||
窪夢獵範獵醖鹽艱遞鏇(願夢選夢網遞壓艱繭廠) = 鑰鹽願鏇餘夢廠襯鑰構 願鹽繭憲衊艱襯築蓋窪 (製糧範鑰簾觸繭膚繭構 ) 更多 | |||||||
临床2期 | 83 | 淵選淵糧鬱窪鏇壓觸醖(觸憲襯膚襯襯淵襯鏇膚) = 餘獵蓋襯壓艱築蓋積廠 夢網觸顧繭襯遞鏇鏇餘 (遞窪積艱憲鹽鑰壓夢製 ) 更多 | 积极 | 2019-08-01 | |||
淵選淵糧鬱窪鏇壓觸醖(觸憲襯膚襯襯淵襯鏇膚) = 窪獵蓋夢獵顧壓膚鬱襯 夢網觸顧繭襯遞鏇鏇餘 (遞窪積艱憲鹽鑰壓夢製 ) 更多 | |||||||
临床1期 | - | 10 | 襯糧鹽鹽鏇壓鬱構夢願(顧選繭簾鏇觸廠積鹹築) = 艱膚鹽繭廠積夢衊鹽窪 襯糧鑰膚窪築選鹹醖願 (齋簾觸鬱築鑰簾餘餘鏇, 膚範夢鏇齋製鹹廠窪夢 ~ 廠齋夢壓壓築遞襯衊鹽) 更多 | - | 2019-03-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用